Document Detail


Histone deacetylases as therapeutic targets - From cancer to cardiac disease.
MedLine Citation:
PMID:  25444758     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Heart failure is a major public health problem in western society. Recently, agents that inhibit histone deacetylase (HDAC) enzymes were developed and approved by the FDA as anticancer agents. This breakthrough has provided the motivation to develop more potent and more selective HDAC inhibitors and to target other pathologic conditions with these drugs. Here we review experimental evidence showing that these drugs may be beneficial in preventing cardiac hypertrophy and heart failure. Several lines of evidence show that inhibitors of Class I HDACs can blunt cardiac hypertrophy and preserve cardiac function in several small animal models. In contrast, Class IIa HDACs appear to be suppressors of hypertrophy, though experimental data with small molecule blockers of this class is largely lacking. The effects of HDAC inhibition in cardiac diseases, the cell population in the heart that is targeted by HDAC blockers, as well as the relative roles of specific HDACs are still under intense investigation.
Authors:
Alon Abend; Izhak Kehat
Related Documents :
25192828 - Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart.
21895968 - Experimental acute myocardial infarction: telocytes involvement in neo-angiogenesis.
25160238 - Correlation between symbolic dynamics analysis indexes and neurohormonal and functional...
25377428 - Protective effect of apigenin on ischemia/reperfusion injury of the isolated rat heart.
15136618 - Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with...
6653608 - Myocardial visualization on a routine perfusion lung scintigram: relationship to the am...
Publication Detail:
Type:  REVIEW     Date:  2014-11-6
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  -     ISSN:  1879-016X     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-3     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Deubiquitinase inhibition as a cancer therapeutic strategy.
Next Document:  Targeting the TGF? pathway for cancer therapy.